Skip to main navigation
  • Contact
  • Careers
  • Home

Karyopharm Test

Menu
  • About
    • Overview
    • Mission
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Sine Technology
  • Drug Candidates
    • Pipeline
    • Oral Selinexor (KPT-330)
    • Oral Verdinexor (KPT-335)
    • Oral KPT-350
    • Oral Dual Inhibitor of PAK4
      and NAMPT (KPT-9274)
    • Investigator Sponsored Trials (IST)
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Ownership Profile
    • Analyst Coverage
    • Investor FAQs
    • Contact Us
    • Email Alerts
    • Investigator Sponsored Trials (IST)
  • Publications
    • Papers
    • Posters and Presentations
  • Patients & Caregivers
    • Patients & Caregivers Overview
    • Clinical Trials
    • Resources
  • Contact
  • Careers

Financials & Filings

Fourth Quarter 2017 Financial Results

Show all

2017

Q4
  • Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
  • Karyopharm Therapeutics 4Q 2017 Earnings Call
  • Form 10-K

Proxy Statements

Filing date View
Apr 28, 2014
0001047469-14-004227.pdf
0001047469-14-004227.rtf
0001047469-14-004227.xls
View HTML
Apr 7, 2015
0001193125-15-121353.pdf
0001193125-15-121353.rtf
0001193125-15-121353.xls
View HTML

Form 10-K

Filing date View
Mar 21, 2014 View HTML
0001047469-14-002800.pdf
0001047469-14-002800.rtf
0001047469-14-002800.xls
EX-101.INS - EX-101.INS
Mar 13, 2015 View HTML
0001193125-15-091264.pdf
0001193125-15-091264.rtf
0001193125-15-091264.xls
EX-101.INS - XBRL INSTANCE DOCUMENT

Form 10-Q

Filing date View
Dec 20, 2013
0001104659-13-091618.pdf
0001104659-13-091618.rtf
0001104659-13-091618.xls
View HTML
Dec 23, 2013
0001104659-13-091964.pdf
0001104659-13-091964.rtf
0001104659-13-091964.xls
EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Investor Relations

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
  • Stock Information
  • Analyst Coverage
  • Investor FAQs
  • Contact Us
  • Investigator Sponsored Trials (IST)

Shareholder Tools







  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • Email
  • RSS

USA
Karyopharm Therapeutics

  • Corporate Headquarters:
  • 85 Wells Ave., 2nd floor
  • Newton, MA 02459
  •  
  • Main Phone Number (USA)
  • 617-658-0600

GERMANY
Karyopharm Therapeutics

  • Sitz der Gesellschaft:
  • Karyopharm Europe GmbH
  • Franziska-Bilek-Weg 9
  • 80339 München
  • Germany
  •  
  • Tel.: +49 (0) 89 – 54 84 86-101
  • Fax: +49 (0) 89 – 54 84 86-200
  • About
  • SINE Technology
  • Drug Candidates
  • Investors
  • Publications
  • Patients & Caregivers
  • Careers
  • Contact

© 2018 Karyopharm Therapeutics

Terms of Use Privacy Policy